via April 18th, 2016 was a life-changing day for people living with keratoconus in the USA; corneal collagen crosslinking, the revolutionary treatment that's been performed in Europe since 1999, was finally approved by the FDA. Keratoconus affects as many as 1 in every 500 people, causing potentially severe vision loss.  But it's progression and causes are poorly understood. During the disease process, the...